Abstract Library

#2904 Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers

Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J,

Keywords: grade 3, prognosis, treatment, alkylating agents,

#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease

Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Sponheim J,

Keywords: Neuroendocrine tumor, Treatment, Radiology, Time to progression,

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,

#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hentic O

Authors: Hentic O, Cros J, Zappa M, Rebours V, Muller N,

Keywords: MGMT, Streptozotocin, PFS ,

#1493 Efficacy and Tolerance of a Simplified Combination of Streptozotocine and Epi-adriamycine in Metastatic Foregut Neuroendocrine Tumor (NET). A Pilot Study

Introduction: Since more than 30 years the combination of Adriamycine (A) and Streptozotocine (STZ) is considered as one of the standard chemotherapy regimens (Moertel et al, N Engl J Med 1992, 326 : 519-23) for patients with aggressive grade 2 metastatic pancreatic NET (PNET).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Hirsch L, Lepère C, Zaanan A, Landi B, Vaillant J,

Keywords: pancreatic NET chemotherapy,